CorMedix Inc. (CRMD)

$3.83

-0.19 (-4.73%)
Rating:
Recommendation:
Buy
Symbol CRMD
Price $3.83
Beta 2.409
Volume Avg. 0.43M
Market Cap 149.842M
Shares () -
52 Week Range 2.65-7.15
1y Target Est -
DCF Unlevered CRMD DCF ->
DCF Levered CRMD LDCF ->
ROE -41.70% Strong Sell
ROA -43.16% Strong Sell
Operating Margin -
Debt / Equity 8.46% Neutral
P/E -
P/B 2.45 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CRMD news


Mr. Khoso Baluch
Healthcare
Biotechnology
NASDAQ Global Market

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.